The development of oral medications provides convenience and improved patient adherence compared to traditional injection or infusion therapies.
Myrobalan’s focus on developing orally available small molecule neurorestorative therapies reflects a broader trend in the pharmaceutical industry. The specific targeting of GPR17 by Myrobalan indicates a trend in precision medicine and personalized therapies. Companies are increasingly identifying specific molecular targets to address the underlying causes of diseases, such as promoting remyelination in neurological conditions. Funding $24 million.